精准生物实体瘤CAR-T细胞疗法登上Nature Cancer：安全有效、毒性可控

Core Viewpoint - CAR-T cell therapy shows significant effectiveness in hematological malignancies but faces challenges in solid tumors, where CEA may serve as a potential immunotherapy target [3]. Group 1: Research Findings - A phase 1 clinical trial published in Nature Cancer evaluated hypoxia-responsive CEA-targeted CAR-T cell therapy for CEA-positive solid tumors, demonstrating safety and promising efficacy [4]. - The trial involved 43 heavily pre-treated patients, with 46.5% having received four or more lines of treatment, divided into intraperitoneal (n=17) and intravenous (n=26) administration groups [7]. - The trial achieved its primary safety endpoint, with 20.9% of patients experiencing grade 3 diarrhea and 76.7% experiencing grade 1-2 cytokine release syndrome [7]. Group 2: Efficacy Results - The disease control rate was 82.4% (objective response rate of 23.5%) in the intraperitoneal group, while the intravenous group had a disease control rate of 68.0% (objective response rate of 8.0%) [7]. - In a subgroup with CEA immunohistochemical expression ≥ 90%, the objective response rate for patients with peritoneal metastasis receiving intraperitoneal therapy was 57.1% (4/7), and for those without liver metastasis receiving intravenous therapy, it was 40.0% (2/5) [7]. - Overall, the trial supports further research into PC13 due to its controllable toxicity and promising efficacy [7].